ATE250420T1 - Verwendung von uridin-triphosphat verwandte verbidungen zur prävention und behandlung von pneumonie in immobilisieren patienten - Google Patents

Verwendung von uridin-triphosphat verwandte verbidungen zur prävention und behandlung von pneumonie in immobilisieren patienten

Info

Publication number
ATE250420T1
ATE250420T1 AT97934275T AT97934275T ATE250420T1 AT E250420 T1 ATE250420 T1 AT E250420T1 AT 97934275 T AT97934275 T AT 97934275T AT 97934275 T AT97934275 T AT 97934275T AT E250420 T1 ATE250420 T1 AT E250420T1
Authority
AT
Austria
Prior art keywords
airways
secretions
patient
mucous
utp
Prior art date
Application number
AT97934275T
Other languages
English (en)
Inventor
Karla M Jacobus
H Jeff Leighton
Original Assignee
Inspire Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inspire Pharmaceuticals Inc filed Critical Inspire Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE250420T1 publication Critical patent/ATE250420T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/10Expectorants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/12Mucolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
AT97934275T 1996-07-23 1997-07-23 Verwendung von uridin-triphosphat verwandte verbidungen zur prävention und behandlung von pneumonie in immobilisieren patienten ATE250420T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08685216 US5763447C1 (en) 1996-07-23 1996-07-23 Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
PCT/US1997/012938 WO1998003182A2 (en) 1996-07-23 1997-07-23 Use of uridine triphosphates and related compounds for the prevention and treatment of pneumonia in immobilized patients

Publications (1)

Publication Number Publication Date
ATE250420T1 true ATE250420T1 (de) 2003-10-15

Family

ID=24751220

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97934275T ATE250420T1 (de) 1996-07-23 1997-07-23 Verwendung von uridin-triphosphat verwandte verbidungen zur prävention und behandlung von pneumonie in immobilisieren patienten

Country Status (12)

Country Link
US (2) US5763447C1 (de)
EP (1) EP0938322B1 (de)
JP (1) JP2000516581A (de)
KR (1) KR20000067983A (de)
CN (1) CN1226169A (de)
AT (1) ATE250420T1 (de)
AU (1) AU727790B2 (de)
CA (1) CA2261674A1 (de)
DE (1) DE69725160T2 (de)
NZ (1) NZ334204A (de)
WO (1) WO1998003182A2 (de)
ZA (1) ZA976538B (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5900407A (en) 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
US6319908B1 (en) 1996-07-03 2001-11-20 Inspire Pharmaceuticals, Inc. Method for large-scale production of di(uridine 5′-tetraphosphate) and salts thereof
US5968913A (en) * 1996-07-03 1999-10-19 Inspire Pharmaceuticals, Inc. Pharmaceutical compositions of uridine triphosphate
US5763447C1 (en) * 1996-07-23 2002-05-07 Inspire Pharmaceuticals Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
WO1998034942A2 (en) 1997-02-06 1998-08-13 Inspire Pharmaceuticals, Inc. Dinucleotides and their use
US6696425B2 (en) 1997-02-06 2004-02-24 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with purinergic receptor agonists
US6921755B2 (en) 1998-02-06 2005-07-26 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with purinergic receptor agonists
US7223744B2 (en) * 1997-02-10 2007-05-29 Inspire Pharmaceuticals, Inc. Pharmaceutical formulation comprising dinucleoside polyphosphates and salts thereof
TW593331B (en) 1997-07-25 2004-06-21 Inspire Pharmaceuticals Inc Method for large-scale production of di(uridine 5')-tetraphosphate and salts thereof
US6462028B2 (en) 1997-07-25 2002-10-08 Inspire Pharmaceuticals, Inc. Method of promoting cervical and vaginal secretions
US6872710B2 (en) * 1997-07-25 2005-03-29 Inspire Pharmaceuticals, Inc. Di(uridine 5′)-tetraphosphate and salts thereof
US6548658B2 (en) * 1997-07-25 2003-04-15 Inspire Pharmaceuticals, Inc. Di-(uridine 5′)-tetraphosphate and salts thereof
CA2295515C (en) * 1997-07-25 2006-03-14 Inspire Pharmaceuticals, Inc. Method for large-scale production of di(uridine 5'-tetraphosphate) and salts thereof
WO1999063927A1 (en) * 1998-06-08 1999-12-16 Michael Lansdale System and method for acupressure therapy
CN100354296C (zh) * 1998-10-02 2007-12-12 雅玛山酱油株式会社 二尿苷四磷酸或其盐的晶体和其制备方法、以及制备该化合物的方法
ATE222920T1 (de) * 1998-10-02 2002-09-15 Yamasa Corp Ein kristall von diuridine tetraphosphat oder ein solches salz und verfahren zu seiner herstellung, verfahren und herstellung der vorgenannten zusammensetzung
US6864243B1 (en) 2000-05-12 2005-03-08 Inspire Pharmaceuticals, Inc. Method for treating retinal degeneration with purinergic receptor agonists
US7018985B1 (en) 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US7452870B2 (en) 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
US7132408B2 (en) 2000-08-21 2006-11-07 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
DE10108851A1 (de) * 2001-02-23 2002-09-12 Resprotect Gmbh Verwendung von 5'-substituierten Nukleosiden und/oder deren Prodrugs zur resistenzfreien Therapie von Infektionskrankheiten
AR034635A1 (es) 2001-06-25 2004-03-03 Inspire Pharmaceuticals Inc Lubricacion de las articulaciones con agonistas del receptor purinergico p2y
KR20050043761A (ko) * 2001-11-06 2005-05-11 인스파이어 파마슈티컬스 인코퍼레이티드 염증성 질환의 치료 또는 예방 방법
US7334580B2 (en) * 2002-05-07 2008-02-26 Smaldone Gerald C Methods, devices and formulations for targeted endobronchial therapy
US7607436B2 (en) * 2002-05-06 2009-10-27 The Research Foundation Of State University Of New York Methods, devices and formulations for targeted endobronchial therapy
GB0417886D0 (en) * 2004-08-11 2004-09-15 Univ Cardiff Method and means for enhanced pulmonary delivery
US7368439B2 (en) * 2005-06-15 2008-05-06 Bar - Ilan University Dinucleoside poly(borano)phosphate derivatives and uses thereof
US7851456B2 (en) * 2005-06-29 2010-12-14 Inspire Pharmaceuticals, Inc. P2Y6 receptor agonists for treating lung diseases
WO2008024169A1 (en) * 2006-07-21 2008-02-28 Glsynthesis, Inc. Reactive pyrophosphoric and bisphosphonic acid derivatives and methods of their use
JP2008199905A (ja) * 2007-02-16 2008-09-04 Snow Brand Milk Prod Co Ltd 乳酸菌生残性向上剤
US8618074B2 (en) * 2007-03-15 2013-12-31 Board Of Regents Of The University Of Texas System GPCR enhanced neuroprotection to treat brain injury
EP2364086B1 (de) 2008-11-20 2016-09-14 Glsynthesis Inc. Neue antithrombotische diadenosintetraphosphate und entsprechende analoga
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
KR20200079572A (ko) * 2015-06-05 2020-07-03 산텐 세이야꾸 가부시키가이샤 소프트 콘택트렌즈가 착용된 드라이아이 환자의 눈에 점안되도록 이용되는 것을 특징으로 하는 드라이아이 치료제
WO2017075535A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
CA3075962A1 (en) * 2017-09-17 2019-03-21 Glenn Fernandes Lung cleansing apparatus and method

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9027968D0 (en) * 1990-12-22 1991-02-13 Fisons Plc Method of treatment
EP0517573A1 (de) * 1991-06-05 1992-12-09 Synthelabo Pharmazeutische Zusammensetzungen zur Behandlung von Atemwegserkrankungen
FR2677250B1 (fr) * 1991-06-05 1995-01-20 Synthelabo Compositions pharmaceutiques contenant de l'adenosine-5-triphosphate disodique.
FR2684299B1 (fr) * 1991-12-02 1995-03-24 Synthelabo Compositions pharmaceutiques contenant de l'adenosine-5-triphosphate disodique et de l'amiloride.
US5292498A (en) * 1991-06-19 1994-03-08 The University Of North Carolina At Chapel Hill Method of treating lung disease with uridine triphosphates
AU7965694A (en) 1993-10-15 1995-05-04 Curators Of The University Of Missouri, The Dna encoding the human p2u receptor and null cells expressing p2u receptors
US5656256A (en) 1994-12-14 1997-08-12 The University Of North Carolina At Chapel Hill Methods of treating lung disease by an aerosol containing benzamil or phenamil
US5635160A (en) * 1995-06-07 1997-06-03 The University Of North Carolina At Chapel Hill Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions
US5628984A (en) 1995-07-31 1997-05-13 University Of North Carolina At Chapel Hill Method of detecting lung disease
JP3519199B2 (ja) 1996-02-06 2004-04-12 株式会社ソニー・コンピュータエンタテインメント 画像生成装置
US5900407A (en) * 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
US6420347B1 (en) * 1997-03-27 2002-07-16 Inspire Pharmaceuticals, Inc. Method of treating ciliary dyskinesia with uridine triphosphates and related compounds
US5837861A (en) 1997-02-10 1998-11-17 Inspire Pharmaceuticals, Inc. Dinucleotides and their use as modulators of mucociliary clearance and ciliary beat frequency
NZ332426A (en) 1996-03-27 2000-09-29 Univ North Carolina Method of treating diseases involving dysfunction of ciliary movement such as ciliary dyskinesia and infertility with uridine triphosphates (UTP) and related compounds
US5789391A (en) 1996-07-03 1998-08-04 Inspire Pharmaceuticals, Inc. Method of treating sinusitis with uridine triphosphates and related compounds
US6319908B1 (en) * 1996-07-03 2001-11-20 Inspire Pharmaceuticals, Inc. Method for large-scale production of di(uridine 5′-tetraphosphate) and salts thereof
US5968913A (en) 1996-07-03 1999-10-19 Inspire Pharmaceuticals, Inc. Pharmaceutical compositions of uridine triphosphate
US5962432A (en) 1996-07-03 1999-10-05 Inspire Pharmaceuticals, Inc. Sterilized, isotonic and pH-adjusted pharmaceutical formulation of uridine triphosphate
US5763447C1 (en) 1996-07-23 2002-05-07 Inspire Pharmaceuticals Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
AU4978897A (en) 1996-10-08 1998-05-05 Inspire Pharmaceuticals, Inc. Method of early lung cancer detection via sputum induction and analysis of sputum to detect cancer associated substances
US6159952A (en) 1996-11-07 2000-12-12 Inspire Pharmaceuticals, Inc. Method of treating bronchitis with uridine triphosphate and related compounds
WO1998034942A2 (en) 1997-02-06 1998-08-13 Inspire Pharmaceuticals, Inc. Dinucleotides and their use
US6462028B2 (en) 1997-07-25 2002-10-08 Inspire Pharmaceuticals, Inc. Method of promoting cervical and vaginal secretions
CA2295515C (en) 1997-07-25 2006-03-14 Inspire Pharmaceuticals, Inc. Method for large-scale production of di(uridine 5'-tetraphosphate) and salts thereof
CA2300146A1 (en) 1997-08-29 1999-03-04 Richard C. Boucher, Jr. Use of uridine 5'-diphosphate and analogs thereof for the treatment of lung diseases
WO1999061012A2 (en) 1998-05-22 1999-12-02 Inspire Pharmaceuticals, Inc. Therapeutic dinucleotide and derivatives
WO2000039145A1 (en) 1998-12-23 2000-07-06 The University Of North Carolina At Chapel Hill Targeted gene transfer using g protein coupled receptors
MXPA01008547A (es) 1999-02-26 2003-06-06 Inspire Pharmaceuticals Inc Metodo para promover la hidratacion de mucosas con ciertos difosfatos de uridina, adenina y citidina, y analogos de estos.
US6555675B2 (en) * 2000-08-21 2003-04-29 Inspire Pharmaceuticals, Inc. Dinucleoside polyphosphate compositions and their therapuetic use as purinergic receptor agonists

Also Published As

Publication number Publication date
DE69725160D1 (de) 2003-10-30
US5763447A (en) 1998-06-09
WO1998003182A3 (en) 1998-05-14
WO1998003182A2 (en) 1998-01-29
US5763447C1 (en) 2002-05-07
ZA976538B (en) 1998-07-09
EP0938322B1 (de) 2003-09-24
US20020155150A1 (en) 2002-10-24
KR20000067983A (ko) 2000-11-25
CA2261674A1 (en) 1998-01-29
JP2000516581A (ja) 2000-12-12
EP0938322A2 (de) 1999-09-01
US6703376B2 (en) 2004-03-09
NZ334204A (en) 2000-07-28
CN1226169A (zh) 1999-08-18
AU727790B2 (en) 2000-12-21
DE69725160T2 (de) 2004-08-12
AU3737597A (en) 1998-02-10

Similar Documents

Publication Publication Date Title
US5763447C1 (en) Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
DE69716255D1 (de) Verfahren zur behandlung von mittelohrentzündung mittels uridintriphosphaten und verwandten mitteln
Carlisle Silicon
US4556557A (en) Method and composition for combating snoring, and the use of surface active substances for the preparation of said composition
DE69736468D1 (de) Verfahren zur behandlung der ziliardyskinesie mit uridintriphosphaten und verwandten verbindungen
ATE231519T1 (de) Dinukleotide zur verwendung in der behandlung von lungenkrankheiten
NO992197L (no) FremgangsmÕte for behandling av bronkitt med uridintrifosfater og relaterte forbindelser
NZ313864A (en) Method of obtaining a mucous sample from the lung using triphosphate compounds
DE69903750D1 (de) Verwendung von langkettigen n-alkyl derivaten von deoxynojirimycin zur herstellung eines medikaments zur behandlung von mit glykolipiden akkumulation zusammenhängenden krankheiten
CA2240717A1 (en) Method of treating and diagnosing sleep disordered breathing and means for carrying out the method
JPH0656672A (ja) 気道障害治療のための医薬組成物
ATE289800T1 (de) Verwendung eines neurologischen wirkstoffes zur herstellung eines medikamentes zur behandlung von erkrankungen des zentralen nervensystems
JP2019532933A5 (de)
ATE161725T1 (de) Verwendung von phosphatdiestern zur behandlung von erkrankungen der retina
EE04330B1 (et) Levosimendani transmukoossed koostised ja nende kasutamine ravimi valmistamiseks
JP2002506009A (ja) 呼吸器疾患および中耳炎の治療
ATE91890T1 (de) Herstellung eines arzneimittels gegen arthritis und rheumatismus.
RU95116663A (ru) Способ лечения острых респираторных вирусных заболеваний и гриппа
SU1536534A1 (ru) Способ лечения острого панкреатита
MXPA98002276A (en) New therapeutic compositions based on silicon biologically act
UA36166A (uk) Спосіб лікування запальних захворювань підшлункової залози
JPH10203988A (ja) 鼻茸および鼻粘膜の浮腫性病変の治療剤
KR840002006A (ko) 포스포르아미드 유도체, 그의 제법 및 그것을 함유하는 의약
RU95104044A (ru) Способ лечения инфекционных заболеваний верхних дыхательных путей, легких и бронхов

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties